my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first in class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapol more
A new report by visiongain predicts that the world market for cancer-treating drugs will reach $75 billion for 2012. That revenue forecast appears in Leading Anti-Cancer Drugs and Associated Market 2012-2022, published in February 2012. The new study predicts that overall revenues for anti-cancer tr more
EvaluatePharma Ltd revealed that Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012 and hold it through 2016. The French drug maker has raced up the rankings over the last decade largely through M&A activity, with the $20bn purchase this year of US biot more
Eli Lilly and Company announced withdrawal of its Xigris® [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients wi more
Innovative drugs are the lifeblood of pharmaceutical companies, but the cost of developing them is rising to unsustainable levels. Pharma executives are already saying that as the economy falters, they foresee bleak prospects and mergers unless their companies get more innovative drugs into their pipelines. The clock is ticking on the race to increase productivity, as key patents worth a projected $30 billion in revenue will expire between 2010 and 2013, opening the floodgates to competition from generics, according to Barbara Ryan, an analyst at Deutsche Bank. This imperative is propelling increased outsourcing of R&D operations as companies trim overcapacity. more
Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of β-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer’s disease (AD). Eli Lilly & Co is developing an intravenous formulation of solanezumab for the treatment of mild-to-moderat more
Peering inside Alzheimer's brains Nature Biotechnology 29, 384 (2011). doi:10.1038/nbt.1863 Author: Gunjan Sinha Last year's failure of Eli Lilly's drug semagacestat in late-stage clinical trials was the latest in a long line of setbacks for novel Alzheimer's therapies. But a more
The patent cliff steepens Nature Reviews Drug Discovery 10, 12 (2011). doi:10.1038/nrd3356 Many blockbuster drugs — including Lipitor (atorvastatin; Pfizer), Plavix (clopidogrel; Sanofi–Aventis/Bristol-Myers Squibb) and Zyprexa (olanzapine; Eli Lilly & Company) — are facing expiry of their U more
Introduction GlobalData, the industry analysis specialist, has released its new report, “Type 2 Diabetes - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global type 2 diabetes therapeutics market. The report provides comp more
TechNavio’s analysts forecast the Global Human Growth Hormone Drug market to grow at a CAGR of 3 percent over the period 2011–2015. One of the key factors contributing to this market growth is the increase in number of people suffering from growth hormone deficiency. The Global Human Growth Hormone more
TechNavio’s analysts forecast the Global Cancer Drug market to grow at a CAGR of 12.6 percent over the period 2010–2014. One of the key factors contributing to this market growth is the increase in the prevalence of cancer worldwide. The Global Cancer Drug market in the Americas, and the EMEA and AP more
Watchlist
This is where you can add this topic to your personal favourites
Eli Lilly and Company Eli Lilly and Company () is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis , Indiana , in the United States . The company was founded ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
